Osvaldo Flores
Plus aucun poste en cours
Fortune : 6 M $ au 31/03/2024
Profil
Osvaldo Flores is the founder of Novira Therapeutics LLC, which was founded in 2009.
He held the title of President & Chief Scientific Officer from 2009 to 2015.
Dr. Flores's former job was as President, Chief Executive Officer & Director at Century Therapeutics, Inc. He also held the title of Vice President-Research & Development at Janssen, Inc. (Nebraska) from 2015 to 2017.
Dr. Flores received a doctorate degree from both the University of Medicine & Dentistry of New Jersey and Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2023 | 1 321 719 ( 1,64% ) | 6 M $ | 31/03/2024 |
Anciens postes connus de Osvaldo Flores
| Sociétés | Poste | Fin |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Chief Executive Officer | 11/04/2023 |
Janssen, Inc. (Nebraska)
 Janssen, Inc. (Nebraska) Miscellaneous Commercial ServicesCommercial Services Janssen, Inc. (Nebraska) is a private company based in Lincoln, NE. The company provides legal services. | Corporate Officer/Principal | 01/12/2017 |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Founder | 01/12/2015 |
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Chief Executive Officer | - |
Formation de Osvaldo Flores
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
Janssen, Inc. (Nebraska)
Janssen, Inc. (Nebraska) Miscellaneous Commercial ServicesCommercial Services Janssen, Inc. (Nebraska) is a private company based in Lincoln, NE. The company provides legal services. | Commercial Services |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |
